Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/262266
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest |
Autor: | Al Shaer, Danah; Al Musaimi, Othman; Albericio, Fernando CSIC ORCID; de la Torre, Beatriz G. | Palabras clave: | FDA Piflufolastat-F18 Antibody-drug conjugate Casimersen Dasiglucagon Difelikefalin Inclisiran Vosoritide Drugs Voclosporin Loncastuximab tesirine-lpyl Melphalan flufenamide odevixibat Oligonucleotides Pegcetacoplan Peptides Tisotumab vedotin-tftv |
Fecha de publicación: | 13-feb-2022 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Pharmaceuticals 15 (2): 222 (2022) | Resumen: | From the medical, pharmaceutical, and social perspectives, 2021 has been a year dominated by the COVID-19 pandemic. However, despite this global health crisis, the pharmaceutical industry has continued its endeavors, and 2021 could be considered an excellent year in terms of the drugs accepted by the US Food and Drug Administration (FDA). Thus, during this year, the FDA has approved 50 novel drugs, of which 36 are new chemical entities and 14 biologics. It has also authorized 10 TIDES (8 peptides, 2 oligonucleotides), in addition to 2 antibody-drug conjugates (ADCs) whose structures contain peptides. Thus, TIDES have accounted for about 24% of the approvals in the various drug categories. Importantly, this percentage has surpassed the figure in 2020 (10%), thus reflecting the remarkable success of TIDES. In this review, the approved TIDE-based drugs are analyzed on the basis of their chemical structure, medical target, mode of action, administration route, and adverse effects. | Versión del editor: | https://doi.org/10.3390/ph15020222 | URI: | http://hdl.handle.net/10261/262266 | DOI: | 10.3390/ph15020222 | ISSN: | 1424-8247 |
Aparece en las colecciones: | (IQAC) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
pharmaceuticals-15-00222.pdf | Artículo principal | 2,38 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
22
checked on 16-may-2024
SCOPUSTM
Citations
50
checked on 15-may-2024
WEB OF SCIENCETM
Citations
38
checked on 23-feb-2024
Page view(s)
59
checked on 21-may-2024
Download(s)
58
checked on 21-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.